Paclitaxel is an anticancer drug used in ovarian cancer, breast cancer and small cell lung carcinoma. The objective of the present investigation was to develop liposomal formulation of Paclitaxel. Dipalmitoylphosphatidylcholine (DPPC), Dipalmitoylphosphatidylglycerol (DPPG) and cholesterol were used to prepare Paclitaxel liposomes. Thin film hydration method was adopted for preparing Paclitaxel liposomes. FTIR study revealed no any interaction between drug and excipients and they were found to be compatible with each other. Drug content and percentage drug entrapment were selected for optimization of liposomal formulations of Paclitaxel. Maximum percentage drug entrapment was found to be 67.08%. Optimized Batch (F5) was characterized for various parameters such as drug content, percentage drug entrapment, particle size, zeta potential, Transmission electron microscopy and photo microscopic study. Optimized batch showed particle size 237.3nm and negative zeta potential -37.9 mV. In vitro drug release study of optimized formulation (F5) showed 41.12% of drug release after 48 h. It was found to be zero-order release. Formulation was stable at 2-8 oC after one month stability study. The result of optimized batch (F5) indicated that sustained release formulation of Paclitaxel could be formulated.
Loading....